The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis

• Published in: Translational cancer research 2021-03, Vol.10 (3), p.1249-1260
• Main Authors: Barlow, Melissa, Hamilton, Willie, Ukoumunne, Obioha C, Bailey, Sarah E R
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2218-676X; 2219-6803
• DOI: 10.21037/tcr-20-3287

Thrombocytosis is associated with poor lung cancer prognosis and has recently been identified as having a high positive predictive value in lung cancer detection. Lung cancer has multiple histological and genetic subtypes and it is not known whether platelet levels differ across these subtypes, or whether thrombocytosis is predictive of a particular subtype. and were systematically searched for studies that reported pre-treatment platelet count, as either averages or proportion of patients with thrombocytosis, by subtype of lung cancer using a pre-specified search strategy. The Newcastle-Ottowa scale was used to assess study quality and risk of bias. Suitable studies were synthesised in meta-analyses and subgroup analyses examined for differences across subtypes. The prevalence of pre-treatment thrombocytosis across all lung cancer patients was 27% (95% CI: 17% to 37%). By subtype, this was 22% (95% CI: 7% to 41%) for adenocarcinoma, 28% (95% CI: 15% to 43%) for squamous cell carcinoma (SCC), 36% (95% CI: 13% to 62%) for large cell carcinoma (LCC), and 30% (95% CI: 8% to 58%) for small cell lung cancer (SCLC). The pooled mean platelet count for lung cancer patients was 289×10 /L (95% CI: 268 to 311). By subtype, this was 282×10 /L (95% CI: 259 to 306) for adenocarcinoma, 297×10 /L (95% CI: 238 to 356) for SCC, 290×10 /L (95% CI: 176 to 404) for LCC, and 293×10 /L (95% CI: 244 to 342) for SCLC. There was no difference in thrombocytosis prevalence (P=0.76) or mean platelet count (P=0.96) across the subtypes. These findings suggest thrombocytosis is no more indicative of one lung cancer subtype over another. We therefore conclude a high platelet count is likely to be generic across all lung cancer subtypes.